Abstract | BACKGROUND: HYPOTHESIS/OBJECTIVES: ANIMALS: Forty one dogs with mild to moderate cAD were recruited by19 animal hospitals. METHODS: Dogs were assigned to receive either the investigational agent (K71 group; n = 20) or cetirizine hydrochloride (control group; n = 21). Previously prescribed medications were allowed to be continued during the 12 week trial. Dogs were assessed by the investigators using the cAD Extent and Severity Index (CADESI) and a medication scoring system. Pet owners assessed their dogs using a visual analog scale (VAS) and pruritus scores. RESULTS: The CADESI scores, VAS and pruritus scores in both groups at 12 weeks were improved compared with their baselines. The CADESI and pruritus scores in the K71 group were slightly lower than those in the control group and the reduction of medication scores in the K71 group was significantly lower compared with the control group (P < 0.05; Student's t-test). CONCLUSIONS AND CLINICAL IMPORTANCE:
|
Authors | Yuri Ohshima-Terada, Yuki Higuchi, Takehisa Kumagai, Akihito Hagihara, Masahiko Nagata |
Journal | Veterinary dermatology
(Vet Dermatol)
Vol. 26
Issue 5
Pg. 350-3, e74-5
(Oct 2015)
ISSN: 1365-3164 [Electronic] England |
PMID | 26123498
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 ESVD and ACVD. |
Chemical References |
- Anti-Allergic Agents
- Cetirizine
|
Topics |
- Animals
- Anti-Allergic Agents
(therapeutic use)
- Cetirizine
(therapeutic use)
- Dermatitis, Atopic
(therapy, veterinary)
- Dog Diseases
(therapy)
- Dogs
- Double-Blind Method
- Female
- Lactobacillus
- Male
- Probiotics
(therapeutic use)
- Treatment Outcome
|